a buyout of $350M / $3 pps gives a 400% premium to current price, and while it is 17 x current revs, factors in EU sales and some pricing power. Not commenting on how likely this is to actually occurr, but its a level the acquirer could justify to it's sharholders, above recent (2 yr) SVNT highs, and would finally put the drug in commercially capable hands. The long time holders get the short end of the deal, but that seems to be imminent. Thank the BOD and mgmt for getting the least shareholder value possible out of K approval through cascading mistakes.
"$3 pps " "a level the acquirer could justify to it's sharholders" "The long time holders get the short end of the deal, but that seems to be imminent."
None of us on this msg bd have the Co data necessary to determine the average CB of all shareholders at any given time, nor that of a legal determined time shareholder class action time period. So, throwing numbers out, like your "$3 pps " is just throwing darts on a dart board. We all are losing patience and want to get this dead money moving again but really backin, you should be ashamed of yourself!
I can't recall offhand what your current position and cost basis is at the moment but mine as you know doubt well know is:
kg2931 (20K Shrs SVNT (BTGC) @ $4.64 Avg CB held since 2/11/1997)
'the average CB of all shareholders' has really nothing to do with actual valuation. What matters is current and potential earnings. current is negative 60M a year, or -85 cents a share on top of net debt of -$2 a share. Potential is limitied in SVNT's hands. You honestly think institutions would reject $3 pps because it's below their CB? Their job is just like ours; get the most you reasonably can out of the stock going fwd. What potential buyer is going to pay $4, $5, or more given what K has so far demonstrated? Growth curve flattened out in the US, mgmt just continuing to deliver excuses as opposed to results, and still yet to launch EU or get a partner which they have been talking about for 3 qtrs...